These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 30568660)

  • 1. Low Percentage of Signal Regulatory Protein α/β
    Magill L; Adriani M; Berthou V; Chen K; Gleizes A; Hacein-Bey-Abina S; Hincelin-Mery A; Mariette X; Pallardy M; Spindeldreher S; Szely N; Isenberg DA; Manson JJ; Jury EC; Mauri C
    Front Immunol; 2018; 9():2865. PubMed ID: 30568660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.
    Kobie JJ; Zheng B; Bryk P; Barnes M; Ritchlin CT; Tabechian DA; Anandarajah AP; Looney RJ; Thiele RG; Anolik JH; Coca A; Wei C; Rosenberg AF; Feng C; Treanor JJ; Lee FE; Sanz I
    Arthritis Res Ther; 2011; 13(6):R209. PubMed ID: 22177419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors.
    Hernández-Breijo B; Navarro-Compán V; Plasencia-Rodríguez C; Parodis I; Gehin JE; Martínez-Feito A; Novella-Navarro M; Mezcua A; Warren DJ; Nozal P; Pascual-Salcedo D; Balsa A
    Sci Rep; 2021 Jun; 11(1):11632. PubMed ID: 34079038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.
    Balsa A; Sanmarti R; Rosas J; Martin V; Cabez A; Gómez S; Montoro M
    Rheumatology (Oxford); 2018 Apr; 57(4):688-693. PubMed ID: 29365183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
    Ulijn E; den Broeder N; Wientjes M; van Herwaarden N; Meek I; Tweehuysen L; van der Maas A; van den Bemt BJ; den Broeder AA
    Ann Rheum Dis; 2020 Jul; 79(7):867-873. PubMed ID: 32317314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Cytokine Inhibition Modulates Activation and Homing Receptors of Peripheral Memory B Cell Subsets in Rheumatoid Arthritis Patients.
    Mahmood Z; Schmalzing M; Dörner T; Tony HP; Muhammad K
    Front Immunol; 2020; 11():572475. PubMed ID: 33042152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TROVE2 Antibody Determined by Immune-Related Array May Serve as a Predictive Marker for Adalimumab Immunogenicity and Effectiveness in RA.
    Chen PK; Lan JL; Chen YM; Chen HH; Chang SH; Chung CM; Rutt NH; Tan TM; Mamat RNR; Anuar ND; Blackburn JM; Chen DY
    J Immunol Res; 2021; 2021():6656121. PubMed ID: 33763493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial.
    Sode J; Krintel SB; Carlsen AL; Hetland ML; Johansen JS; Hørslev-Petersen K; Stengaard-Pedersen K; Ellingsen T; Burton M; Junker P; Østergaard M; Heegaard NHH
    J Rheumatol; 2018 Jan; 45(1):53-61. PubMed ID: 29142030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up.
    Chen DY; Chen YM; Hsieh TY; Hung WT; Hsieh CW; Chen HH; Tang KT; Lan JL
    Rheumatology (Oxford); 2016 Jan; 55(1):143-8. PubMed ID: 26324949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No Correlation between Anti-drug Antibodies and Therapeutic Response in Tunisian Patients with Chronic Inflammatory Diseases Treated by TNF Blockers.
    Bouden S; Laadhar L; Soua J; Ben Messaoud M; Rouached L; Ayadi I; Saidane O; Ben Tekaya A; Mahmoud I; Rekik S; Srairi HS; Tekaya R; Bellakhal S; Fekih M; Abdelmoula L; Kallel M
    Curr Rheumatol Rev; 2024; 20(4):435-443. PubMed ID: 38314598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved adalimumab dose decision with comprehensive diagnostics data.
    Zänker M; Becher G; Arbach O; Maurer M; Stuhlmüller B; Schäfer A; Strohner P; Brand J
    Clin Exp Rheumatol; 2018; 36(1):136-139. PubMed ID: 28850025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pneumocystis pneumonia developed in two patients with rheumatoid arthritis during treatment of adalimumab].
    Ikeuchi H; Umemoto A; Tsukida M; Sakurai N; Maeshima A; Kuroiwa T; Hiromura K; Nojima Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(5):420-5. PubMed ID: 22041430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
    Soubrier M; Pereira B; Frayssac T; Fan A; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
    Int J Rheum Dis; 2018 Nov; 21(11):1924-1932. PubMed ID: 28901727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study.
    Hoxha A; Calligaro A; Tonello M; Ramonda R; Carletto A; Paolazzi G; Bortolotti R; Del Ross T; Grava C; Boaretto M; Favaro M; Teghil V; Ruffatti A; Punzi L
    Joint Bone Spine; 2016 Mar; 83(2):167-71. PubMed ID: 26750762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?
    Cuppen BV; Rossato M; Fritsch-Stork RD; Concepcion AN; Schenk Y; Bijlsma JW; Radstake TR; Lafeber FP;
    Arthritis Res Ther; 2016 Aug; 18(1):189. PubMed ID: 27558398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.
    Capsoni F; Sarzi-Puttini P; Atzeni F; Minonzio F; Bonara P; Doria A; Carrabba M
    Arthritis Res Ther; 2005; 7(2):R250-5. PubMed ID: 15743471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
    Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
    Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis.
    Chara L; Sánchez-Atrio A; Pérez A; Cuende E; Albarrán F; Turrión A; Chevarria J; Sánchez MA; Monserrat J; de la Hera A; Prieto A; Sanz I; Diaz D; Alvarez-Mon M
    Arthritis Res Ther; 2012 Jul; 14(4):R175. PubMed ID: 22838733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.